Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Ko, Sae Hee ^a,b   Nauta, Allison ^a,c   Morrison, Shane D ^a   Zhou, Hongyan ^d   Zimmermann, Andrew ^a,e   Gurtner, Geoffrey C ^a   Ding, Sheng ^a   Longaker, Michael T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROXOLAMINE; HYPOXIA INDUCIBLE FACTOR 1; ANTIFUNGAL AGENT; CICLOPIROX; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PYRIDONE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC WOUND; DRUG ACTIVITY; DRUG EFFICACY; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; WOUND CLOSURE; WOUND HEALING; ANIMAL; CELL LINE; CELL STRAIN 3T3; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; TIME; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIFUNGAL AGENTS; BLOTTING, WESTERN; CELL LINE; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NIH 3T3 CELLS; PYRIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 81355142726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027844     Document Type: Article

References (35)

1. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
2. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, et al. (2009) Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 17: 763-771.
3. Wieman TJ, Smiell JM, Su Y, (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21: 822-827.
4. Frykberg RG, (1999) Epidemiology of the diabetic foot: ulcerations and amputations. Adv Wound Care 12: 139-141.
5. Tandara AA, Mustoe TA, (2004) Oxygen in wound healing--more than a nutrient. World J Surg 28: 294-300.
6. Covello KL, Simon MC, (2004) HIFs, hypoxia, and vascular development. Curr Top Dev Biol 62: 37-54.
7. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, et al. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864.
8. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, et al. (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93: 1074-1081.
9. Li W, Li Y, Guan S, Fan J, Cheng CF, et al. (2007) Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J 26: 1221-1233.
10. Chan DA, Sutphin PD, Yen SE, Giaccia AJ, (2005) Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25: 6415-6426.
11. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090.
12. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, et al. (2003) The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB J 17: 761-763.
13. Galiano RD, Michaels Jt, Dobryansky M, Levine JP, Gurtner GC, (2004) Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen 12: 485-492.
14. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, et al. (2001) The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 18: 133-138.
15. Armstrong DG, Lavery LA, Harkless LB, (1998) Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 21: 855-859.
16. Jeffcoate WJ, Chipchase SY, Ince P, Game FL, (2006) Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 29: 1784-1787.
17. Martin A, Komada MR, Sane DC, (2003) Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23: 117-145.
18. Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, et al. (2008) A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 24 (Suppl 1): S119-144.
19. Cross KJ, Mustoe TA, (2003) Growth factors in wound healing. Surg Clin North Am 83: 531-545 vi.
20. Beer HD, Longaker MT, Werner S, (1997) Reduced expression of PDGF and PDGF receptors during impaired wound healing. J Invest Dermatol 109: 132-138.
21. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, et al. (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164: 1935-1947.
22. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, et al. (2007) Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 117: 1249-1259.
23. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, et al. (2009) The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 106: 13505-13510.
24. Botusan IR, Sunkari VG, Savu O, Catrina AI, Grunler J, et al. (2008) Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A 105: 19426-19431.
25. Fang RC, Kryger ZB, Buck DW, De la Garza M, Galiano RD, et al. (2010) Limitations of the db/db mouse in translational wound healing research: Is the NONcNZO10 polygenic mouse model superior? Wound Repair Regen 18: 605-613.
26. Michaels J, Churgin SS, Blechman KM, Greives MR, Aarabi S, et al. (2007) db/db mice exhibit severe wound-healing impairments compared with other murine diabetic strains in a silicone-splinted excisional wound model. Wound Repair Regen 15: 665-670.
27. Subissi A, Monti D, Togni G, Mailland F, (2010) Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70: 2133-2152.
28. Fung ML, Li M, Lahiri S, (2007) Increased endogenous nitric oxide release by iron chelation and purinergic activation in the rat carotid body. Open Biochem J 1: 1-6.
29. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, et al. (2009) Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538.
30. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, et al. (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114: 3064-3073.
31. Hinz B, (2007) Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 127: 526-537.
32. Darby IA, Hewitson TD, (2007) Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 257: 143-179.
33. Brenner MA, Harkless LB, Mendicino RW, Page JC, (2007) Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. J Am Podiatr Med Assoc 97: 195-202.
34. Mayser P, Freund V, Budihardja D, (2009) Toenail onychomycosis in diabetic patients: issues and management. Am J Clin Dermatol 10: 211-220.
35. Seluanov A, Vaidya A, Gorbunova V, (2010) Establishing primary adult fibroblast cultures from rodents. J Vis Exp.